Alembic Pharma

₹1002.8 -0.4 | 0%

WEBSITE BSE:533573 NSE : ALEM PHARMA 10 May, 16:01

Market Cap ₹19710 Cr.

Stock P/E 32.0

P/B 4.1

Current Price ₹1002.8

Book Value ₹ 245.1

Face Value 2

52W High ₹1093.1

Dividend Yield 1.1%

52W Low ₹ 536.6

Edit Ratio

Alembic Pharma Research see more...

Overview Inc. Year: 2010Industry: Pharmaceuticals & Drugs

Alembic Pharmaceuticals Ltd is a pharmaceutical organisation. The Company is engaged developing formulations and active pharmaceutical ingredients (API). The Company specializes in analgesic, cough anti-infective, and cold therapies. It additionally focuses on cures, including gastrointestinal, orthopedic, dermatology, cardiology, diabetes, gynecology, and ophthalmology. Its APIs consist of independent production blocks for Macrolides, non-steroidal anti-inflammatory pills (NSAIDs) and different capsules. The Company gives global and home formulations. Under home components, it offers Branded Formulations and Generic formulations. Its domestic formula include Revas H, Lactonic, Folinal, Gestofit, Roxid, Zofix, Althrocin, Tellzy AH, Glisen 1/2, Glimser 1/2, Veldrop, Azithral, Brinzemic and Neolap. Its usual formulations include Alcephin, Alcizon, Baciclox, Comeba, Furobid, Cetral, Ephedrex CD, Sicor, Worid, O Win Suspension, O win T, Silomag Gel, Pentab, Aginal AT and Pyremol.

Alembic Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Alembic Pharma Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	1272	1416	1262	1475	1509	1406	1486	1595	1631	1517
Other Income	15	10	1	0	0	1	12	10	3	4
Total Income	1287	1426	1263	1475	1509	1407	1498	1605	1633	1521
Total Expenditure	1030	1256	1247	1242	1260	1194	1287	1387	1364	1257
Operating Profit	257	170	16	233	249	213	210	218	269	264
Interest	4	7	9	12	15	14	14	16	15	11
Depreciation	56	123	67	68	67	74	66	68	69	69
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	197	41	-60	153	168	125	130	135	185	183
Provision for Tax	29	7	-2	18	33	-36	9	-2	4	5
Profit After Tax	168	34	-59	135	136	161	121	137	181	179
Adjustments	4	-12	-7	-2	-14	-8	-0	-1	-0	-0
Profit After Adjustments	172	22	-66	133	122	153	121	137	180	178
Adjusted Earnings Per Share	8.7	1.1	-3.4	6.8	6.2	7.8	6.1	6.9	9.2	9.1

Alembic Pharma Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	1520	1863	2056	3166	3135	3131	3935	4606	5393	5306	5653	6229
Other Income	17	4	12	9	3	35	27	14	87	50	3	29
Total Income	1537	1868	2068	3175	3137	3166	3962	4620	5481	5356	5656	6257
Total Expenditure	1272	1506	1661	2161	2520	2516	3079	3392	3913	4432	4945	5295
Operating Profit	265	361	407	1014	617	650	883	1228	1568	925	711	961
Interest	24	10	4	5	5	3	18	27	16	18	50	56
Depreciation	35	40	44	72	83	105	115	157	183	287	275	272
Exceptional Income / Expenses	0	0	0	0	0	0	0	-44	0	0	0	0
Profit Before Tax	206	311	359	936	529	541	749	1000	1368	625	355	633
Provision for Tax	41	75	76	216	122	120	157	199	253	104	13	16
Profit After Tax	165	236	283	720	407	421	593	801	1115	521	342	618
Adjustments	0	0	0	0	-4	-8	-8	28	32	0	0	-1
Profit After Adjustments	165	236	283	720	403	413	584	829	1147	521	342	616
Adjusted Earnings Per Share	8.8	12.5	15	38.2	21.4	21.9	31	44	58.3	26.5	17.4	31.3

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	7%	7%	13%	14%
Operating Profit CAGR	-23%	-17%	2%	10%
PAT CAGR	-34%	-25%	-4%	8%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	74%	1%	13%	14%
ROE Average	7%	15%	19%	28%
ROCE Average	7%	15%	18%	29%

Alembic Pharma Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	503	676	885	1597	1902	2220	2719	3219	5067	5238	4370
Minority's Interest	0	0	0	0	0	0	-1	-29	0	0	0
Borrowings	71	52	19	0	0	500	499	887	200	0	0
Other Non-Current Liabilities	33	42	54	84	94	76	71	160	161	162	52
Total Current Liabilities	529	603	908	944	814	1267	1664	1954	1533	1831	1641
Total Liabilities	1135	1372	1865	2626	2811	4064	4952	6192	6961	7230	6064
Fixed Assets	344	397	547	708	799	993	1158	1552	1788	1798	2398
Other Non-Current Assets	71	119	204	209	517	1123	1662	1974	2269	2458	751
Total Current Assets	719	857	1115	1708	1494	1948	2132	2665	2904	2975	2914
Total Assets	1135	1372	1865	2626	2811	4064	4952	6192	6961	7230	6064

Alembic Pharma Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	47	16	24	23	439	153	84	199	72	98	61
Cash Flow from Operating Activities	265	240	172	948	329	312	812	449	1463	552	724
Cash Flow from Investing Activities	-67	-81	-256	-307	-486	-884	-756	-732	-839	-372	-448
Cash Flow from Financing Activities	-229	-151	87	-224	-129	503	59	155	-597	-217	-262
Net Cash Inflow / Outflow	-31	8	3	417	-286	-69	115	-128	27	-37	14
Closing Cash & Cash Equivalent	16	24	27	439	153	84	199	72	98	61	75

Alembic Pharma Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	8.77	12.49	15.01	38.2	21.39	21.89	31	43.97	58.33	26.5	17.4
CEPS(Rs)	10.62	14.64	17.35	42.03	25.99	27.92	37.55	50.82	66.05	41.09	31.41
DPS(Rs)	2.5	3	3.5	4	4	4	5.5	10	14	10	8
Book NAV/Share(Rs)	26.68	35.84	46.93	84.74	100.92	117.78	144.24	170.79	257.8	266.47	222.36
Core EBITDA Margin(%)	16.26	19.08	19.08	31.75	19.61	19.65	21.75	26.36	27.44	16.48	12.53
EBIT Margin(%)	15.06	17.16	17.52	29.74	17.05	17.4	19.51	22.3	25.66	12.12	7.16
Pre Tax Margin(%)	13.5	16.6	17.34	29.57	16.88	17.29	19.04	21.71	25.37	11.79	6.27
PAT Margin (%)	10.81	12.59	13.65	22.74	12.98	13.44	15.06	17.38	20.67	9.82	6.05
Cash Profit Margin (%)	13.09	14.75	15.79	25.02	15.63	16.81	17.99	20.8	24.07	15.22	10.92
ROA(%)	14.79	18.79	17.47	32.07	14.97	12.25	13.15	14.37	16.95	7.34	5.15
ROE(%)	36.81	39.97	36.24	58.02	23.25	20.42	24	26.97	26.91	10.11	7.12
ROCE(%)	32.05	43.54	37.54	65.86	28.87	22.15	22.66	23.3	26.28	11.25	7.44
Receivable days	51.58	49.38	55.91	41.02	40.13	50.43	47.09	53.64	41.06	39.75	59.84
Inventory Days	62.73	56.34	61.11	54.91	70.01	79.67	78.91	85.38	90.48	106.49	99.6
Payable days	134.46	153.8	174.95	197.26	219.27	259.49	258.05	223.04	187.92	173.51	148.05
PER(x)	11.88	22.72	30.2	15.72	29.16	25.12	17.11	12.14	16.55	27.97	28.5
Price/Book(x)	3.9	7.92	9.66	7.09	6.18	4.67	3.68	3.12	3.74	2.78	2.23
Dividend Yield(%)	2.4	1.06	0.77	0.67	0.64	0.73	1.04	1.87	1.45	1.35	1.61
EV/Net Sales(x)	1.4	2.92	4.27	3.47	3.73	3.51	2.78	2.55	3.59	2.85	1.82
EV/Core EBITDA(x)	8.04	15.04	21.56	10.83	18.93	16.89	12.37	9.55	12.35	16.37	14.49
Net Sales Growth(%)	3.75	22.55	10.35	53.98	-0.99	-0.12	25.68	17.06	17.1	-1.62	6.54
EBIT Growth(%)	16.02	39.37	13.04	159.47	-43.25	1.94	40.95	33.77	34.77	-53.53	-37.06
PAT Growth(%)	26.99	42.51	20.05	154.68	-43.49	3.44	40.78	35.11	39.23	-53.27	-34.35
EPS Growth(%)	26.99	42.51	20.13	154.52	-44.01	2.35	41.62	41.83	32.66	-54.56	-34.35
Debt/Equity(x)	0.37	0.16	0.3	0.07	0.05	0.32	0.42	0.54	0.1	0.12	0.15
Current Ratio(x)	1.36	1.42	1.23	1.81	1.84	1.54	1.28	1.36	1.89	1.63	1.78
Quick Ratio(x)	0.86	0.91	0.81	1.24	1.06	0.96	0.7	0.76	0.93	0.75	0.88
Interest Cover(x)	9.6	30.87	95.3	173.4	102.16	160.2	41.7	37.81	86.4	36.27	8.07
Total Debt/Mcap(x)	0.1	0.02	0.03	0.01	0.01	0.07	0.11	0.17	0.03	0.04	0.07

Alembic Pharma Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	69.48	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61
FII	5.89	6.02	5.94	5.32	4.99	4.55	4.34	4.5	4.52	4.46
DII	11.6	11.74	12.15	12.54	12.76	13.31	13.64	14.22	14.5	15.39
Public	13.03	12.63	12.3	12.53	12.65	12.53	12.4	11.67	11.37	10.54
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	13.66	13.68	13.68	13.68	13.68	13.68	13.68	13.68	13.68	13.68
FII	1.16	1.18	1.17	1.05	0.98	0.89	0.85	0.89	0.89	0.88
DII	2.28	2.31	2.39	2.47	2.51	2.62	2.68	2.79	2.85	3.02
Public	2.56	2.48	2.42	2.46	2.49	2.46	2.44	2.29	2.23	2.07
Others	0	0	0	0	0	0	0	0	0	0
Total	19.66	19.66	19.66	19.66	19.66	19.66	19.66	19.66	19.66	19.66

Pros

Debtor days have improved from 173.51 to 148.05days.
Company is almost debt free.

Cons

Stock is trading at 4.1 times its book value.
The company has delivered a poor profit growth of -4% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Alembic Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Alembic Pharma

Add Watchlist

Alembic Pharma Research see more...

Overview Inc. Year: 2010Industry: Pharmaceuticals & Drugs

Alembic Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Alembic Pharma Quarterly Results

Alembic Pharma Profit & Loss

Growth Rates

Alembic Pharma Balance Sheet

Alembic Pharma Cash Flow

Alembic Pharma Ratios

Alembic Pharma Shareholding Pattern

Alembic Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!